이 리포트에서는 2020-2025년 의약품 업계의 라이선싱 계약 상세를 제공하고 있습니다. 당사자 간에 발표된 라이선싱 계약 결제 조건에 대한 액세스를 제공하고, 결제 조건 및 기타 거래조건에 대해 유익한 인사이트를 제공합니다.
주요 이점
이 리포트는 독자에게 아래의 주요 이점을 제공합니다. :
2020년 이후 계약 동향에 대한 이해
라이선싱 계약 열람
벤치마크 분석 : 거래의 시장가치 파악
재무 조건 : 일시금, 마일스톤, 로열티에 관한 정보
계약 디렉토리 : 기업별(A-Z), 치료 분야별, 기술 유형별
주요 계약 : 금액별
가장 활발한 계약 체결 기업의 식별
각 거래의 자산 및 계약 조건의 식별
계약 문서에 대한 액세스 : 계약 구조에 관한 인사이트
듀 딜리전스 : 제휴 기업에 대한 자사 계약 조건의 적합성 평가
수백 시간의 조사 시간 절약 가능
조사 범위
바이오 제약 업계에서 라이선싱 계약의 동향
라이선싱 계약 구조의 개요
제약 및 바이오테크놀러지 분야에서 라이선싱 계약 기록 디렉토리
계약금액이 큰 주요 라이선싱 계약
가장 활발하게 라이선싱 계약을 시행하고 있는 기업
주요 라이선싱 제휴 리소스
이용 가능한 계약 리스트 :
기업(A-Z)
계약 총액
치료 분야
기술 유형
목차
개요
제1장 서론
제2장 라이선싱 거래의 동향
라이선싱 계약의 정의
2020년 이후 라이선싱 계약의 동향
2020-2025년에서 라이선싱 계약 : 연별
2020-2025년에서 라이선싱 계약 : 개발 단계별
2020-2025년에서 라이선싱 계약 : 업계별
2020-2025년에서 라이선싱 계약 : 치료 영역별
2020-2025년에서 라이선싱 계약 : 기술 유형별
2020-2025년에서 라이선싱 계약 : 가장 활발한 기업별
라이선싱 제휴 계약을 체결하는 이유
라이선싱 계약의 미래
제3장 라이선싱 계약 구조 : 개요
라이선싱 계약 구조
제4장 주요 라이선싱 계약
TOP 라이선싱 계약 : 금액별
제5장 가장 활발한 라이선싱 계약 기업 : TOP 25사
가장 활발한 라이선싱 계약 기업 : TOP 25사
제6장 계약 디렉토리를 포함한 라이선싱 계약
2020-2025년 계약을 포함한 라이선싱 계약
계약 디렉토리
계약 디렉토리 - 기업별 라이선싱 계약(A-Z)
계약 디렉토리 - 치료 영역별 라이선싱 계약
계약 디렉토리 - 기술 유형별 라이선싱 계약
Biopharma Research 소개
현재 제휴
현재 계약
Current Partnering으로부터의 최근 리포트 타이틀
KSA
영문 목차
영문목차
Licensing Deals in Pharmaceuticals provides a detailed understanding and analysis of how and why companies enter licensing deals.
Fully revised and updated, the report provides details of licensing deals from 2020 to 2025.
The report provides access to licensing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of licensing dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in licensing as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of licensing deals.
Chapter 4 provides a review of the leading licensing deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active licensing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of licensing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2020 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the licensing deal.
The deal directory includes a comprehensive listing of all licensing deals announced since 2020. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2020.
In conclusion, this report provides everything a prospective dealmaker needs to know about licensing alliances.
Key benefits
Licensing Deals in Pharmaceuticals provides the reader with the following key benefits:
Understand deal trends since 2020
Browse licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Report scope
Licensing Deals in Pharmaceuticals is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading biopharma companies worldwide.
Licensing Deals in Pharmaceuticals includes:
Trends in licensing dealmaking in the biopharma industry
Overview of licensing deal structure
Directory of licensing deal records covering pharmaceutical and biotechnology
The leading licensing deals by value
Most active licensing dealmakers
The leading licensing partnering resources
In Licensing Deals in Pharmaceuticals, the available deals are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Licensing Deals in Pharmaceuticals provides comprehensive access to available records for licensing deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
What are the rights granted or optioned?
What rights are granted by the agreement?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are intellectual property rights handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in licensing dealmaking
2.1. Introduction
2.2. Definition of licensing deal
2.3. Trends in licensing deals since 2020
2.3.1. Licensing dealmaking by year, 2020-2025
2.3.2. Licensing dealmaking by phase of development, 2020-2025
2.3.3. Licensing dealmaking by industry sector, 2020-2025
2.3.4. Licensing dealmaking by therapy area, 2020-2025
2.3.5. Licensing dealmaking by technology type, 2020-2025
2.3.6. Licensing dealmaking by most active company, 2020-2025
2.4. Reasons for entering into licensing partnering deals
2.5. The future of licensing deals
Chapter 3 - Overview of licensing deal structure
3.1. Introduction
3.2. Licensing agreement structure
Chapter 4 - Leading licensing deals
4.1. Introduction
4.2. Top licensing deals by value
Chapter 5 - Top 25 most active licensing dealmakers
5.1. Introduction
5.2. Top 25 most active licensing dealmakers
Chapter 6 - Licensing deals including contracts directory
6.1. Introduction
6.2. Licensing deals with contracts 2020-2025
Deal directory
Deal directory - licensing dealmaking by companies A-Z
Deal directory - licensing dealmaking by therapy area
Deal directory - licensing dealmaking by technology type
About Biopharma Research
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of licensing
Figure 2: Trends in licensing deal announcements, 2020-2025
Figure 3: Licensing deals signed at each phase of development, 2020-2025
Figure 4: Licensing deals by industry sector, 2020-2025
Figure 5: Licensing deals by therapy area, 2020-2025
Figure 6: Licensing deals by technology type, 2020-2025
Figure 7: Top 25 most active licensing dealmakers, 2020-2025
Figure 8: Top licensing deals by value, 2020-2025
Figure 9: Most active licensing dealmakers, 2020-2025
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
